Spruce Biosciences (SPRB)
(Real Time Quote from BATS)
$0.47 USD
-0.01 (-1.88%)
Updated Aug 28, 2024 01:08 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SPRB 0.47 -0.01(-1.88%)
Will SPRB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SPRB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRB
Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue Estimates
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates
SPRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
Pfizer (PFE) Q1 Earnings and Revenues Beat Estimates
Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know
Other News for SPRB
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kronos Bio (KRON), Spruce Biosciences (SPRB) and scPharmaceuticals (SCPH)
Spruce Biosciences GAAP EPS of -$0.22 beats by $0.01, revenue of $1.61M beats by $0.69M
Analysts Offer Insights on Healthcare Companies: Meiragtx Holdings (MGTX), Spruce Biosciences (SPRB) and Gossamer Bio (GOSS)
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates